# OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026
Canonical URL: https://biopharmsignal.com/news/LCTX/opregenr-3-year-results-in-patients-with-ga-presented-at-foundation-fighting-blindness-retinal-innovation-summit-2026
Ticker: LCTX
Company: Lineage Cell Therapeutics
Source: Lineage Cell Therapeutics
Published: 2026-05-04 12:00 EST
Original Source URL: https://investor.lineagecell.com
## Summary

Gains in best corrected visual acuity (BCVA) of +9 letters at 36 months among patients with extensive coverage of OpRegen cell therapy to the geographic atrophy (GA) lesion site OCT imaging indicated partial restoration of outer retinal structure, re-appearance of an RPE layer, and features

## Article Body
Gains in best corrected visual acuity (BCVA) of +9 letters at 36 months among patients with extensive coverage of OpRegen cell therapy to the geographic atrophy (GA) lesion site OCT imaging indicated partial restoration of outer retinal structure, re-appearance of an RPE layer, and features
## Recent Company News
- 2026-05-12 20:01 EST — [Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/LCTX/lineage-cell-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Lineage Cell Therapeutics
- 2026-05-05 12:00 EST — [Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026](https://biopharmsignal.com/news/LCTX/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026) — Source: Lineage Cell Therapeutics
- 2026-05-04 12:00 EST — [OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026](https://biopharmsignal.com/news/LCTX/opregenr-3-year-results-in-patients-with-ga-presented-at-foundation-fighting-blindness-retinal-innovation-summit-2026) — Source: Lineage Cell Therapeutics
- 2026-04-13 12:00 EST — [Lineage Announces Formation of Scientific Advisory Board](https://biopharmsignal.com/news/LCTX/lineage-announces-formation-of-scientific-advisory-board) — Source: Lineage Cell Therapeutics
- 2026-03-24 12:00 EST — [Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease](https://biopharmsignal.com/news/LCTX/lineage-launches-new-cell-therapy-program-in-corneal-endothelial-disease) — Source: Lineage Cell Therapeutics
## Related News
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)
- 2026-07-22 20:01 EST — AXON — [Axon to Release Second Quarter 2026 Earnings on August 5, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902)
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)
- 2026-07-22 12:30 EST — NRSN — [NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS](https://biopharmsignal.com/news/NRSN/neurosense-advances-primec-toward-new-drug-submission-to-health-canada-for-als-721c198c)